We have found that Ole promotes cytotoxicity of Dacarbazine (DTIC), a guanine methylating agent, whose treatment, was approved by the Food and Drug Administration (FDA) and of the mTOR inhibitor Everolimus (RAD001), and that its combination with RAD001 was also an effective strategy in treating Vemurafenib (PLX4032)-resistant BRAF melanoma cells, where Vemurafenib (PLX4032) is a BRAF inhibitor. Here, MTOR is linked to melanoma.